BioCentury
ARTICLE | Clinical News

Alnylam preclinical data

January 6, 2014 8:00 AM UTC

In a mouse model of obesity and mixed hyperlipidemia, subcutaneous doses of 3 mg/kg ALN-ANG reduced triglyceride levels from baseline by >=95%, LDL-C levels by >=85% and total cholesterol by >=60%. Da...